Dan Arias

Management directly attributed China's strength to industrial double-digit growth, with lab expected to improve in H2.

Shawn emphasized agility on cost and pricing mitigation, with tariff benefits and inflation headwinds roughly offsetting.

Shawn said the changes were mostly rounding, with better China momentum offset modestly by softer Western markets.

Patrick attributed retail strength to project timing and innovation, not market recovery. Q1 guided high single digit but FY2026 flattish due to tough comps. Two years of new product introductions competing very well.

Patrick described pharmacopeia as continuous upgrade opportunity supporting lab growth, not a step change. Good customer engagement in Q3-Q4. Involves minimum weight requirements and ultrapure water quality monitoring compliance.

Shawn guided both China lab and industrial to low single digit for 2026. China Pharmacopoeia update and GLP-1 investments as lab upside. Industrial had first growth in 2 years in Q3. Team visit 1.5 months ago was encouraging.

Patrick said MTD well positioned with 50% production/QA/QC sales exposure. Moderate 2026 impact, more in 2027. Currently in planning phase with key accounts on pharma and semiconductor reshoring.

Shawn confirmed $0.40 is gross headwind. No Q3 impact due to inventory levels. Q4 has limited mitigation time. Already have straw man for 2026 full offset.

Shawn noted increasingly positive trends before Swiss announcement. Industrial was a highlight. Patrick added China came in better than guided in Q2, second half expected flattish.

Shawn acknowledged surcharges would need to be pulled back if rates change but noted supply chain investments in Mexico are permanent competitive advantages.

Shawn confirmed Mexico now produces lab, industrial, and food retail products after facility expansion. Significantly broader than original pipette/reagent scope.

Shawn confirmed core Industrial still cautious but product inspection tracking to high single-digit in Q1 on momentum carry-forward.

Shawn confirmed bioprocessing improvement affirmed in Q4 but noted biotech/liquid handling still mixed. Lab guided mid- to high single-digit ex-delays.

Jim indicated mid-single-digit Q4 growth achievable largely on easier comps without significant biotech or academic step up, though improvement in those could be upside.

Kim confirmed current pull-through at $45K per instrument per year with target of $90K as multiomics adoption scales. Broadening antibody portfolio for spatial and expanding RNA probe capabilities. Described as multi-quarter or more than a year play.

Jim confirmed the math: Q1 was +1% ex-2 customers, Q2 guide implies +3% ex-2 customers, demonstrating meaningful underlying acceleration despite total growth remaining roughly flat.

Kim declined to quantify individual customer concentration citing high variability in order sizes by indication and clinical phase. Emphasized the 700-customer pipeline total as evidence of diversification beyond the two Fast Track customers.

Kim confirmed EBITDA threshold is close and could be triggered with a little business tailwind, potentially allowing earlier acquisition than the December 2027 backstop date.

Jim explained that approximately 50-55% of US academic funding comes from federal sources, with roughly 50% of federal from NIH specifically. Combined with 12% US academic revenue share, total NIH exposure is less than one-third of academic.

Jim confirmed that even modeling a 40% academic revenue cut with gradual recovery to 3-5% historical growth, the company would still achieve double-digit growth over a five-year period given academic was never the key growth driver in the strategic plan.

Kim provided TTM growth of a little over 30% but deflected quarterly specifics citing lumpiness from Phase III ordering patterns. Noted quarterly swings of 90%, 60%, 10% across recent quarters.

Jim declined specific Q3 guidance for GMP reagents but noted TTM ~40% growth. Called GMP reagents the second most profitable product line, very close to core RUO reagents in profitability.

Marc cited higher commodity prices and increased safety and security demand as the growth drivers.

Marc framed Q1 in-line performance as risk retirement, noted customer sentiment is strong particularly in pharma/biotech, and explained the inflation cushion as prudent given uncertainty.

Jim quantified Q1 organic growth headwinds as ~1pp from selling days and ~1pp from pharma services phasing, confirming normalized Q1 growth closer to 3%.

Casper said pharma customers have good confidence navigating government policies with excitement around their pipelines, and biotech funding sentiment is incredibly positive though there is a spending lag.

Casper confirmed mid-single-digit plus is the right framing for 2026 biopharma growth, with different paths to reach the 3-4% total organic target.

Casper said China pricing pressure is less pronounced in industrial and pharma vs diagnostics, with pharma and biotech growing modestly in the quarter.

Casper saw nice momentum from biotech with strong clinical research activity, pharma services early traction, and M&A transactions helping the broader ecosystem.

Casper said mid-single-digit pharma growth was the best in 9 quarters with broad strength, and customer tone from both small biotech and large pharma is incredibly positive.

Williamson noted positive book-to-bill but said tariff guidance assumptions for H2 remain pessimistic on China demand; improvement there would help.

Prahlad attributed improvement to combination of funding, M&A activity, and greater policy/regulatory clarity. Noted need to see durability over longer period before calling true uptake.

Prahlad highlighted Signals is in its most significant NPI phase ever (Biodesign, Synthetica, Labgistics). Reiterated aspiration to double software revenue in 4-5 years (~15% organic CAGR).

Prahlad specified activity is concentrated in large and mid-sized biotech, which are traditional RVTY customers. Smaller/emerging biotech conversations ongoing but at lower activity levels.

Max clarified $10M was full H2 contribution (started modestly in Q3, picks up in Q4). Q4 run rate becomes consistent quarterly baseline for FY26.

Max confirmed ~$10M in H2 for Genomics England, mostly in Q4, with strong early visibility from first month of operations.

Prahlad maintained VBP hasn't impacted RVTY but acknowledged government's broader cost-reduction focus across DRG, Sunshine Act, and VBP.

Max guided Signals to upper-teens for full year with strong double-digit H2, maintaining confidence in LRP targets.

Prahlad declined to comment on specific deals but emphasized strong organic profile post-transformation, active but not M&A-dependent.

CFO noted chemistry and software launches are margin-accretive, offsetting initial instrument launch costs; value engineering underway on Alliance iS/TQ.

Management framed biosimilars as significant volume growth opportunity with lower prices driving higher penetration and access.

Management attributed TA softness to U.S. order timing, with strong China battery testing partially offsetting.

Management acknowledged early traction in drug metabolism (DMPK) but declined to elaborate further for competitive reasons.

CFO clarified MS growth is driven by its own innovation across PFAS, clinical and bioanalytical characterization, not LC replacement.

Management described the PFAS opportunity as still in early innings, with multiple testing layers from academic to remediation.

Eric said the durable 25% growth reflects many levers; Jim said nothing is implied on volume.

Eric expects tumor-naive data in lung and CRC next year, possibly bleeding into 2027.

Jim guided data growth to around 30% for the year, declining to give quarterly unit-level guidance.

Eric said MRD demand is strong across naive and informed, with volumes gated pending reimbursement.

Jim declined to give exact Ambry ASPs but attributed the 2024 accelerant to higher cash collections.